Paloma Partners Management Co Increases Stake in Catalent, Inc. (NYSE:CTLT)

Paloma Partners Management Co increased its position in Catalent, Inc. (NYSE:CTLT - Free Report) by 345.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,179 shares of the company's stock after acquiring an additional 19,523 shares during the period. Paloma Partners Management Co's holdings in Catalent were worth $1,525,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of CTLT. Millennium Management LLC increased its position in shares of Catalent by 129.2% during the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company's stock valued at $229,416,000 after purchasing an additional 2,299,784 shares during the last quarter. Bank of Montreal Can raised its position in Catalent by 181.5% in the third quarter. Bank of Montreal Can now owns 1,813,167 shares of the company's stock worth $109,388,000 after acquiring an additional 1,169,044 shares during the period. Healthcare of Ontario Pension Plan Trust Fund boosted its stake in shares of Catalent by 166.5% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,382,424 shares of the company's stock worth $83,733,000 after acquiring an additional 863,624 shares during the last quarter. ING Groep NV grew its position in shares of Catalent by 162.5% during the 3rd quarter. ING Groep NV now owns 1,130,504 shares of the company's stock valued at $68,475,000 after acquiring an additional 699,851 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec purchased a new stake in shares of Catalent in the 3rd quarter worth $39,082,000.

Insider Activity

In other news, insider David Mcerlane sold 1,994 shares of the business's stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now directly owns 36,304 shares in the company, valued at $2,177,150.88. The trade was a 5.21 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares of the company's stock, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,114 shares of company stock worth $305,931 over the last 90 days. Corporate insiders own 0.31% of the company's stock.

Catalent Price Performance

CTLT traded up $0.29 on Tuesday, hitting $61.72. 4,220,956 shares of the company's stock traded hands, compared to its average volume of 1,828,331. Catalent, Inc. has a one year low of $36.74 and a one year high of $62.08. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The firm has a market cap of $11.20 billion, a price-to-earnings ratio of -27.31, a P/E/G ratio of 2.44 and a beta of 1.15. The company's 50 day simple moving average is $59.96 and its 200-day simple moving average is $58.60.

Catalent (NYSE:CTLT - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. Catalent's quarterly revenue was up 4.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.10) EPS. As a group, research analysts anticipate that Catalent, Inc. will post 0.84 EPS for the current year.

Analyst Ratings Changes

CTLT has been the topic of several analyst reports. Robert W. Baird reiterated a "neutral" rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. Baird R W downgraded Catalent from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. StockNews.com raised shares of Catalent from a "sell" rating to a "hold" rating in a report on Monday. Finally, William Blair reaffirmed a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. Eight analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $63.40.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.